Latest News
Prelude Therapeutics Incorporated
- Prelude Therapeutics Spotlights JAK2, KAT6A Programs and Potential $100M Incyte Option
- Prelude Therapeutics secures Lilly deal. Citizens targets Prelude Therapeutics stock at USD 6.00
- Prelude Therapeutics at Chardan conference: bet on selective degraders
- Prelude Therapeutics to present at Chardan Heal...
- Prelude Therapeutics to Participate in the Chardan Healthcare Conference
- Prelude Therapeutics to Participate in the Chardan Healthcare Conference
- Wilmington's Prelude Therapeutics Partners With Lilly to Test KAT6A Degrader PRT13722 With Verzenio® and Inluriyo® in HR+/HER2- Breast Cancer
- Citizens reiterates Prelude Therapeutics stock rating on Lilly deal
- Wainwright targets Prelude Therapeutics stock at USD 8.00
- Prelude Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate KAT6A Selective Degrader PRT13722 in Combination with Verzenio® and Inluriyo® in Patients with HR+/HER2- Breast Cancer
- Prelude Therapeutics Teams Up With Lilly To Test Experimental Breast Cancer Drug In Phase 1 Trial
- Lilly will supply two drugs for Prelude's planned breast cancer trial.
Headlines from the last 30 days, linking to the original publishers. See all market news →